A Biomathematical Model of Human Erythropoiesis under Erythropoietin and Chemotherapy Administration

Anaemia is a common haematologic side effect of dose-dense multi-cycle cytotoxic polychemotherapy requiring erythrocyte transfusions or erythropoietin (EPO) administration. To simulate the effectiveness of different EPO application schedules, we performed both modelling of erythropoiesis under chemotherapy and pharmacokinetic and dynamic modelling of EPO applications in the framework of a single comprehensive biomathematical model. For this purpose, a cell kinetic model of bone marrow erythropoiesis was developed that is based on a set of differential compartment equations describing proliferation and maturation of erythropoietic cell stages. The system is regulated by several feedback loops comprising those mediated by EPO. We added a model of EPO absorption after injection at different sites and a pharmacokinetic model of EPO derivatives to account for the effects of external EPO applications. Chemotherapy is modelled by a transient depletion of bone marrow cell stages. Unknown model parameters were determined by fitting the predictions of the model to data sets of circulating erythrocytes, haemoglobin, haematocrit, percentage of reticulocytes or EPO serum concentrations derived from the literature or cooperating clinical study groups. Parameter fittings resulted in a good agreement of model and data. Depending on site of injection and derivative (Alfa, Beta, Delta, Darbepoetin), nine groups of EPO applications were distinguished differing in either absorption kinetics or pharmacokinetics. Finally, eight different chemotherapy protocols were modelled. The model was validated on the basis of scenarios not used for parameter fitting. Simulations were performed to analyze the impact of EPO applications on the risk of anaemia during chemotherapy. We conclude that we established a model of erythropoiesis under chemotherapy that explains a large set of time series data under EPO and chemotherapy applications. It allows predictions regarding yet untested EPO schedules. Prospective clinical studies are needed to validate model predictions and to explore the feasibility and effectiveness of the proposed schedules.     

Suppression of Erythropoiesis by Alcohol

Serial measurements in alcoholic subjects showed a profound fall of serum iron for three days after withdrawal of alcohol and a reversion of abnormal accumulation of erythroblastic haemosiderin to normal. These findings suggest an interference in normal haem synthesis, most probably by a direct effect.     

转线粒体细胞模型

转线粒体细胞模型是由无线粒体DNA(mtDNA)细胞与mtDNA供体通过融合的方法而形成的融合细胞。随着转线粒体技术的发展,制备该细胞模型的方法也多种多样。现今,转线粒体模型的应用十分广泛,不仅可应用于线粒体相关疾病的基础研究,而且在线粒体相关疾病的临床研究中也发挥了重要的作用。融合细胞具有一致的核背景,可以消除核基因的作用,因而有助于判断mtDNA突变的致病作用及机制和线粒体缺陷的致病作用及机制。此外,利用该模型还可作为探讨线粒体相关疾病基因治疗和筛选疾病治疗药物的有效模型。     

红细胞生成的转录调节多因子的协调作用

红细胞由造血干细胞分化而成,此过程包含复杂转录因子的相互作用,这些转录因子调节下游基因的表达并介导分化与增生信号,红细胞谱系的多能干细胞的定型诱导血细胞生成.主要综述了适应红细胞发育的广谱因子及特殊因子,这些因子单独操纵或部分参与转录、激活或表达.     

A Synthetic Model of Human Beta-Thalassemia Erythropoiesis Using CD34+ Cells from Healthy Adult Donors

Based upon the lack of clinical samples available for research in many laboratories worldwide, a significant gap exists between basic and clinical studies of beta-thalassemia major. To bridge this gap, we developed an artificially engineered model for human beta thalassemia by knocking down beta-globin gene and protein expression in cultured CD34+ cells obtained from healthy adults. Lentiviral-mediated transduction of beta-globin shRNA (beta-KD) caused imbalanced globin chain production. Beta-globin mRNA was reduced by 90% compared to controls, while alpha-globin mRNA levels were maintained. HPLC analyses revealed a 96% reduction in HbA with only a minor increase in HbF. During the terminal phases of differentiation (culture days 14–21), beta-KD cells demonstrated increased levels of insoluble alpha-globin, as well as activated caspase-3. The majority of the beta-KD cells underwent apoptosis around the polychromatophilic stage of maturation. GDF15, a marker of ineffective erythropoiesis in humans with thalassemia, was significantly increased in the culture supernatants from the beta-KD cells. Knockdown of beta-globin expression in cultured primary human erythroblasts provides a robust ex vivo model for beta-thalassemia.     

Hybrid Mixture Model for Subpopulation Identification

Personalized medicine aims to identify those patients who have good or poor prognosis for overall disease outcomes or therapeutic efficacy for a specific treatment. A well-established approach is to identify a set of biomarkers using statistical methods with a classification algorithm to identify patient subgroups for treatment selection. However, there are potential false positives and false negatives in classification resulting in incorrect patient treatment assignment. In this paper, we propose a hybrid mixture model taking uncertainty in class labels into consideration, where the class labels are modeled by a Bernoulli random variable. An EM algorithm was developed to estimate the model parameters, and a parametric bootstrap method was used to test the significance of the predictive variables that were associated with subgroup memberships. Simulation experiments showed that the proposed method averagely had higher accuracy in identifying the subpopulations than the Naïve Bayes classifier and logistic regression. A breast cancer dataset was analyzed to illustrate the proposed hybrid mixture model.